Evaluation of Circulating Tumor DNA as a Biomarker for Chemoresistance in Colorectal Cancer Authors: Koduvayur Roopa Lakshmi, Charan Sankar Sankaranarayanan, Raja A. S. Gogineni, K. Afsar Shaheen, Parasharan Peddi Published: 2025 ABSTRACT Background:Colorectal cancer (CRC) is a leading cause of cancer-related mortality globally. Resistance to chemotherapy, particularly to first-line regimens such as FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin), remains a critical barrier to successful treatment.Methods:This prospective observational study enrolled 96 patients with stage II–IV colorectal adenocarcinoma receiving first-line FOLFOX chemotherapy. Plasma samples were collected at baseline, post-cycle 3, and post-cycle 6 for ctDNA quantification and sequencing of KRAS, NRAS, and TP53 mutations. Radiological tumor response was assessed by RECIST v1.1 criteria. Statistical analysis included ANOVA, Chi-square tests, and logistic regression.Results:Among 96 patients (mean age 60.3 ± 8.2 years; 58.3% male), 34 (35.4%) exhibited chemoresistance. Baseline ctDNA levels were significantly higher in resistant patients (38.7 ± 10.5 ng/mL) compared to responders (25.4 ± 9.3 ng/mL, P < 0.001). TP53 mutations were more frequent in resistant patients (58.8% vs. 27.9%, P = 0.004). A >20% reduction in ctDNA by cycle 3 was associated with treatment response (OR 4.12, 95% CI 1.76–9.67, P = 0.001). ROC curve analysis yielded an AUC of 0.84 for ctDNA reduction as a predictor of chemoresistance.Conclusion:Elevated baseline ctDNA levels and persistent TP53 mutations are associated with chemoresistance in colorectal cancer. Early reduction in ctDNA during therapy may serve as a robust predictor of response, supporting its integration into personalized treatment strategies. INTRODUCTION Colorectal cancer (CRC) ranks as the third most commonly diagnosed cancer and the second leading cause of cancer-related deaths worldwide, accounting for approximately 1.9 million new cases and 935,000 deaths annually.[1] The mainstay of systemic treatment for advanced CRC involves chemotherapy regimens such as FOLFOX or FOLFIRI, often combined with targeted therapies. However, intrinsic and acquired resistance to chemotherapy significantly limits therapeutic efficacy and patient outcomes.[2] Recently, circulating tumor DNA (ctDNA) has emerged as a potential biomarker for early cancer detection, prognosis, and monitoring therapeutic response. ctDNA consists of small fragments of DNA shed from tumor cells into the bloodstream and reflects the genomic landscape of the tumor.[3] Multiple studies have shown that dynamic changes in ctDNA levels correlate with tumor burden and treatment response across various malignancies.[4] In CRC, detection of KRAS, NRAS, and TP53 mutations via ctDNA has been explored for monitoring disease progression and minimal residual disease.[56] MATERIALS AND METHODS A total of 96 patients with histologically confirmed colorectal adenocarcinoma, stages II to IV, were enrolled after obtaining informed consent. Inclusion criteria Age 18–75 years Age 18–75 years ECOG performance status ≤2 ECOG performance status ≤2 Initiating first-line FOLFOX chemotherapy Initiating first-line FOLFOX chemotherapy Measurable disease as per RECIST v1.1. Measurable disease as per RECIST v1.1. Exclusion criteria Prior chemotherapy or radiotherapy Prior chemotherapy or radiotherapy Co-existing malignancies Co-existing malignancies Active infections or severe comorbidities Active infections or severe comorbidities Inadequate organ function. Inadequate organ function. Peripheral blood (10 mL) was collected in EDTA tubes at three time points: baseline (T0), post-cycle 3 (T1), and post-cycle 6 (T2). Plasma was isolated within 2 hours and stored at − 80°C. ctDNA was extracted using the QIAamp Circulating Nucleic Acid Kit (Qiagen). Quantification was performed using droplet digital PCR. Targeted next-generation sequencing (NGS) was used to identify mutations in KRAS, NRAS, and TP53 genes. All patients received FOLFOX chemotherapy every two weeks. Tumor response was assessed using CT imaging after 6 cycles, according to RECIST v1.1 criteria. Patients were categorized as responders (complete or partial response) or resistant (stable or progressive disease). Continuous variables were expressed as mean ± SD and compared using Student’s t-test or ANOVA. RESULTS A total of 96 patients were included, with a mean age of 60.3 ± 8.2 years; 56 (58.3%) were male and 40 (41.7%) were female. Most patients had stage III (45.8%) or IV (41.7%) disease. The primary tumor was located in the rectum (52.1%) or left colon (30.2%). Following 6 cycles of FOLFOX, 62 patients (64.6%) were classified as responders, and 34 (35.4%) were resistant. There were no significant differences in baseline demographics or tumor stage between groups. Baseline ctDNA levels were significantly elevated in the resistant group (38.7 ± 10.5 ng/mL) compared to responders (25.4 ± 9.3 ng/mL, P < 0.001). By cycle 3, responders showed a >20% reduction in ctDNA (mean: −28.5 ± 11.3%), while resistant patients showed minimal change (−5.4 ± 7.2%, P < 0.001). Mutation analysis revealed TP53 mutations in 20 of 34 resistant patients (58.8%) versus 17 of 62 responders (27.9%) (P = 0.004). KRAS and NRAS mutations did not differ significantly between groups. A >20% decline in ctDNA by T1 was associated with response (OR 4.12; 95% CI 1.76–9.67; P = 0.001). The ROC curve for ctDNA reduction yielded an AUC of 0.84 (95% CI 0.76–0.91), with 81% sensitivity and 78% specificity for predicting response [Table 1]. Table 1Predictive value of ctDNA reduction at cycle 3 for chemotherapy responseVariableResponders (n=62)Resistant (n=34) P ctDNA % reduction at T1 (mean±SD)−28.5±11.3%−5.4±7.2%<0.001**≥20% ctDNA reduction (%)51 (82.3%)9 (26.5%)<0.001**<20% ctDNA reduction (%)11 (17.7%)25 (73.5%)<0.001**Odds Ratio for ≥20% reduction4.12 (95% CI: 1.76–9.67)–0.001**AUC of ROC curve0.84––Sensitivity (%)81.0––Specificity (%)78.2––**Highly significant Predictive value of ctDNA reduction at cycle 3 for chemotherapy response **Highly significant DISCUSSION Our study demonstrates that circulating tumor DNA (ctDNA) is a promising non-invasive biomarker for predicting chemoresistance in patients with colorectal cancer undergoing FOLFOX chemotherapy. Elevated baseline ctDNA levels and lack of early decline were significantly associated with treatment resistance. These findings align with prior reports suggesting that ctDNA dynamics reflect tumor burden and biological response to chemotherapy.[7] A prospective study by Reinert et al.[8] showed that ctDNA clearance correlated with minimal residual disease and recurrence risk in CRC. Similarly, Tie et al.[9] reported that persistent ctDNA after adjuvant chemotherapy predicted relapse in stage III CRC. Our results extend these findings by focusing on early chemoresistance rather than recurrence, offering a real-time tool for treatment adaptation. The observed association between TP53 mutations and chemoresistance is also consistent with prior evidence indicating that TP53 alterations may promote genomic instability and therapeutic resistance.[10] In contrast, KRAS and NRAS mutations did not differ significantly between groups, suggesting that their predictive utility may be limited in this context, as also noted by Benesova et al.[11] CONCLUSION This study provides compelling evidence that elevated baseline ctDNA levels and a lack of early decline during FOLFOX chemotherapy are significantly associated with chemoresistance in colorectal cancer. Conflicts of interest There are no conflicts of interest.